Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement June 25, 2026 at 10:35 AM UTC
Internal link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform June 25, 2026 at 10:25 AM UTC
Internal link ProQR Announces First Quarter 2026 Operating and Financial Results May 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform May 11, 2026 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 May 04, 2026 at 12:00 PM UTC
Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors April 30, 2026 at 12:00 PM UTC
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 March 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook January 08, 2026 at 01:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 November 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference October 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals October 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals October 29, 2018 at 11:33 AM UTC
Internal link ProQR to Present at the Chardan Genetic Medicines Conference October 02, 2018 at 11:00 AM UTC